Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SHR-8068 + chemoradiotherapy as perioperative treatment for resectable locally advanced rectal cancer
CTR20260677Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab, CS1002 in rectal adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2026; status: active.
02
Drugs
adebrelimabCS1002
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on CTR20260677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260677.